Burden and Prevention of Adverse Cardiac Events in Patients with Concomitant Chronic Heart Failure and Coronary Artery Disease: A Literature Review
Open Access
- 18 May 2016
- journal article
- review article
- Published by Wiley in Cardiovascular Therapeutics
- Vol. 34 (3) , 152-160
Abstract
Summary: Background: Chronic heart failure (HF) or coronary artery disease (CAD) confers risk for thromboembolism and secondary adverse cardiac events (ACEs) (e.g., mortality, myocardial infarction, and stroke). When HF and CAD occur concomitantly, ACE risk is reported to be elevated. We investigated ACEs, their epidemiology, and the resulting burden among patients with concomitant HF and CAD through a structured review of recent literature. Antithrombotic treatment for ACE prevention was assessed.Methods: Pertinent databases (PubMed, other) were searched for relevant articles published from January 2004 to March 2015. Data collected included ACE incidence, healthcare resource use, costs, change in quality of life attributed to ACEs, and treatment practice for prevention of ACEs in patients with concomitant HF and CAD.Results: Mortality rates for patients with both HF and CAD ranged from 4.9–12.3% at 30 days to 13.7–86% for periods between 9.9 months and 10 years. Incidence of ACEs among HF patients with CAD is, respectively, at least 82% and 15% higher than for patients without HF or without CAD, except for stroke investigated in two studies. All‐cause and HF‐related hospitalization is the main driver of the economic burden in patients with HF, the majority of whom had CAD origin. Despite high prevalence of ischemic complications, there is limited evidence to support the use of warfarin‐type antithrombotics among HF patients.Conclusion: This study confirms that patients with concomitant HF and CAD are at elevated risk for ACEs and suggests the need for effective new antithrombotic treatments to further decrease ischemic complication rates in this population.Keywords
Funding Information
- Bayer HealthCare Pharmaceuticals
This publication has 43 references indexed in Scilit:
- Trends From 1996 to 2007 in Incidence and Mortality Outcomes of Heart Failure After Acute Myocardial Infarction: A Population‐Based Study of 20 812 Patients With First Acute Myocardial Infarction in Western AustraliaJournal of the American Heart Association, 2013
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESCEuropean Heart Journal, 2012
- Rivaroxaban in Patients with a Recent Acute Coronary SyndromeNew England Journal of Medicine, 2012
- Coronary artery disease, coronary revascularization, and outcomes in chronic advanced systolic heart failureInternational Journal of Cardiology, 2011
- Coronary-Artery Bypass Surgery in Patients with Left Ventricular DysfunctionNew England Journal of Medicine, 2011
- Clinical epidemiology of heart failureHeart, 2007
- Prognostic effect of renal dysfunction after ST-segment elevation myocardial infarction with and without heart failureInternational Journal of Cardiology, 2006
- Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programmeEuropean Heart Journal, 2005
- Sudden cardiovascular death following myocardial infarction: The importance of left ventricular systolic dysfunction and congestive heart failureInternational Journal of Cardiology, 2005
- Impaired renal function in patients with ischemic and nonischemic chronic heart failure: association with neurohormonal activation and survivalAmerican Heart Journal, 2004